A vaccine developed by Oxford University and AstraZeneca held up against the highly transmissible variant first detected in the U.K. and had similar protection …
A vaccine developed by Oxford University and AstraZeneca held up against the highly transmissible variant first detected in the U.K. and had similar protection when compared to other strains, according to new data. The variant has been the main driver of coronavirus disease in the U.K. since the middle of December due to rapid spread, Prof. Andrew Pollard, director of the Oxford Vaccine Group and chief investigator of the Oxford vaccine trial, previously told an advisory panel for the Centers for Disease Control and Prevention (CDC). The new findings, posted ahead of rigorous peer review in „Preprints with The Lancet“ on Thursday, compared the vaccine’s efficacy among other strains. „Data from our trials of the ChAdOx1 vaccine in the United Kingdom indicate that the vaccine not only protects against the original pandemic virus but also protects against the novel variant, B.
